Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1975 May;55(5):1082–1089. doi: 10.1172/JCI108009

Fitzgerald Trait

Deficiency of a Hitherto Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular Permeability (PF/Dil)

Hidehiko Saito 1,2,3, Oscar D Ratnoff 1,2,3, Robert Waldmann 1,2,3, Joseph P Abraham 1,2,3
PMCID: PMC301855  PMID: 16695963

Abstract

The prolonged partial thromboplastin time observed in the plasma of a 71-yr-old asymptomatic man was related to the deficiency of a hitherto unrecognized agent. The patient's plasma also exhibited impaired surface-mediated fibrinolysis and esterolytic activity and impaired generation of kinins and of the property enhancing vascular permeability designated PF/Dil. The patient's plasma contained normal amounts of all known clotting factors except Fletcher factor (a plasma prekallikrein) which was present at a concentration of 10-15% of pooled normal plasma. Fletcher trait plasma, however, contained normal amounts of the agent missing from the patient's plasma and corrected the defects in clotting, fibrinolysis, and vascular permeability. Fletcher trait plasma was less effective in correcting generation of kinins and esterolytic activity, presumably because of the patient's partial deficiency of prekallikrein. The site of action of the factor deficient in the patient's plasma appeared to be subsequent to the activation of Hageman factor and plasma prekallikrein. A fraction of normal plasma, devoid of other clotting factors, corrected the defect in clotting in the patient's plasma; a similar fraction of the patient's plasma did not correct this abnormality. No evidence yet exists pointing to the familial nature of the patient's defect. Tentatively, the patient's disorder may be referred to by his surname as Fitzgerald trait, and the agent apparently deficient in his plasma as Fitzgerald factor.

Full text

PDF
1082

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colman R. W., Mason J. W., Sherry S. The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med. 1969 Oct;71(4):763–773. doi: 10.7326/0003-4819-71-4-763. [DOI] [PubMed] [Google Scholar]
  2. DINIZ C. R., CARVALHO I. F. A micromethod for determination of bradykininogen under several conditions. Ann N Y Acad Sci. 1963 Feb 4;104:77–89. doi: 10.1111/j.1749-6632.1963.tb17654.x. [DOI] [PubMed] [Google Scholar]
  3. Davies G. E., Holman G., Johnston T. P., Lowe J. S. Studies on kallikrein: failure of some anti-inflammatory drugs to affect release of kinin. Br J Pharmacol Chemother. 1966 Nov;28(2):212–217. doi: 10.1111/j.1476-5381.1966.tb01887.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Donaldson V. H., Saito H., Ratnoff O. D. Defective esterase and kinin-forming activity in human Fletcher trait plasma. A fraction rich in kallikreinlike activity. Circ Res. 1974 May;34(5):652–662. doi: 10.1161/01.res.34.5.652. [DOI] [PubMed] [Google Scholar]
  5. Eisen V. Kinin formation and fibrinolysis in human plasma. J Physiol. 1963 May;166(3):514–529. doi: 10.1113/jphysiol.1963.sp007120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hathaway W. E., Belhasen L. P., Hathaway H. S. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood. 1965 Nov;26(5):521–532. [PubMed] [Google Scholar]
  7. Kaplan A. P., Austen K. F. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med. 1972 Dec 1;136(6):1378–1393. doi: 10.1084/jem.136.6.1378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. LEVY L. R., LEPOW I. H. Assay and properties of serum inhibitor of C'l-esterase. Proc Soc Exp Biol Med. 1959 Aug-Sep;101:608–611. doi: 10.3181/00379727-101-25034. [DOI] [PubMed] [Google Scholar]
  9. MILES A. A., WILHELM D. L. Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation. I. An activable permeability factor and its inhibitor in guinea-pig serum. Br J Exp Pathol. 1955 Feb;36(1):71–81. [PMC free article] [PubMed] [Google Scholar]
  10. Melmon K. L., Cline M. J., Hughes T., Nies A. S. Kinins: possible mediators of neonatal circulatory changes in man. J Clin Invest. 1968 Jun;47(6):1295–1302. doi: 10.1172/JCI105821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. NIEWIAROWSKI S., PROU-WARTELLE O. [Role of the contact factor (Hageman factor) in fibrinolysis]. Thromb Diath Haemorrh. 1959 Sep 1;3:593–603. [PubMed] [Google Scholar]
  12. Ogston D., Ogston C. M., Ratnoff O. D., Forbes C. D. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest. 1969 Oct;48(10):1786–1801. doi: 10.1172/JCI106145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. RATNOFF O. D., DAVIE E. W. The purification of activated Hageman factor (activated factor XII). Biochemistry. 1962 Nov;1:967–975. doi: 10.1021/bi00912a005. [DOI] [PubMed] [Google Scholar]
  14. RATNOFF O. D., MILES A. A. THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR. Br J Exp Pathol. 1964 Jun;45:328–345. [PMC free article] [PubMed] [Google Scholar]
  15. Saito H., Goldsmith G., Ratnoff O. D. Fletcher factor activity in plasmas of various species. Proc Soc Exp Biol Med. 1974 Nov;147(2):519–523. doi: 10.3181/00379727-147-38378. [DOI] [PubMed] [Google Scholar]
  16. Saito H., Ratnoff O. D. Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein): a potential link between the intrinsic and extrinsic blood-clotting systems. J Lab Clin Med. 1975 Mar;85(3):405–415. [PubMed] [Google Scholar]
  17. Saito H., Ratnoff O. D., Donaldson V. H. Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma. Circ Res. 1974 May;34(5):641–651. doi: 10.1161/01.res.34.5.641. [DOI] [PubMed] [Google Scholar]
  18. Saito H., Ratnoff O. D., Marshall J. S., Pensky J. Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin. J Clin Invest. 1973 Apr;52(4):850–861. doi: 10.1172/JCI107249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schiffman S., Lee P. Preparation, characterization, and activation of a highly purified factor XI: evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII. Br J Haematol. 1974 May;27(1):101–114. doi: 10.1111/j.1365-2141.1974.tb06778.x. [DOI] [PubMed] [Google Scholar]
  20. Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971 Jan;50(1):244–254. doi: 10.1172/JCI106480. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES